Effect of anti-vascular endothelial growth factor (VEGF) drugs in chronic central serous chorioretinopathy (CSC)

Effect of anti-vascular endothelial growth factor (VEGF) drugs in chronic central serous chorioretinopathy (CSC) - Effect of anti-VEGF drugs in chronic CSC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014110

Enrollment

Registered

2014-06-01

Start date

2014-06-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic central serous chorioretinopathy

Interventions

ranibizumab pegaputanib aflibercept

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Willingness to provide written informed consent 2) Chronic CSC on fluorescein angiography (FA), indocyanine green angiography (IA), optical coherence tomography (OCT)

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
1) Ratio of patients with improved/maintained best-corrected visual acuity (BCVA) at month 1,3,6,12 2) Ratio of patients with improved central retinal thickness (CRT) at month 1,3,6,12	—

Secondary

Measure	Time frame
Change of BCVA, CRT etc.	—

Countries

Japan

Contacts

Public ContactTsuyoshi Otsuji

Kansai medical university medical center Department of Ophthalmology

otsuji@takii.kmu.ac.jp06-6992-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026